WallStSmart

Cosmos Health Inc. (COSM)vsHenry Schein Inc (HSIC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Henry Schein Inc generates 19161% more annual revenue ($13.38B vs $69.49M). HSIC leads profitability with a 3.0% profit margin vs -30.4%. HSIC earns a higher WallStSmart Score of 52/100 (C-).

COSM

Hold

41

out of 100

Grade: D

Growth: 6.7Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 4/9Altman Z: -2.45

HSIC

Buy

52

out of 100

Grade: C-

Growth: 4.7Profit: 5.5Value: 6.7Quality: 5.0
Piotroski: 2/9Altman Z: 2.37
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for COSM.

HSICUndervalued (+46.6%)

Margin of Safety

+46.6%

Fair Value

$152.96

Current Price

$83.69

$69.27 discount

UndervaluedFair: $152.96Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COSM2 strengths · Avg: 10.0/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
30.7%10/10

Revenue surging 30.7% year-over-year

HSIC1 strengths · Avg: 8.0/10
Price/BookValuation
2.9x8/10

Reasonable price relative to book value

Areas to Watch

COSM4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$10.69M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-106.6%2/10

ROE of -106.6% — below average capital efficiency

Free Cash FlowQuality
$-1.08M2/10

Negative free cash flow — burning cash

HSIC4 concerns · Avg: 3.8/10
PEG RatioValuation
1.824/10

Expensive relative to growth rate

P/E RatioValuation
25.0x4/10

Moderate valuation

EPS GrowthGrowth
4.5%4/10

4.5% earnings growth

Profit MarginProfitability
3.0%3/10

3.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : COSM

The strongest argument for COSM centers on Price/Book, Revenue Growth. Revenue growth of 30.7% demonstrates continued momentum.

Bull Case : HSIC

The strongest argument for HSIC centers on Price/Book.

Bear Case : COSM

The primary concerns for COSM are EPS Growth, Market Cap, Return on Equity.

Bear Case : HSIC

The primary concerns for HSIC are PEG Ratio, P/E Ratio, EPS Growth. Thin 3.0% margins leave little buffer for downturns.

Key Dynamics to Monitor

COSM profiles as a hypergrowth stock while HSIC is a value play — different risk/reward profiles.

COSM carries more volatility with a beta of 4.12 — expect wider price swings.

COSM is growing revenue faster at 30.7% — sustainability is the question.

COSM generates stronger free cash flow (-1M), providing more financial flexibility.

Bottom Line

HSIC scores higher overall (52/100 vs 41/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cosmos Health Inc.

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Cosmos Holdings Inc. is a vertically integrated pharmaceutical company. The company is headquartered in Chicago, Illinois.

Henry Schein Inc

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Henry Schein, Inc. is an American distributor of health care products and services with a presence in 32 countries.

Visit Website →

Want to dig deeper into these stocks?